Literature DB >> 11873542

Oropharyngeal hymenoptera stings: a special concern for airway obstruction.

Brian A Smoley1.   

Abstract

Hymenoptera stings are common and cause 40 to 50 deaths each year. Hymenoptera venom contains a variety of toxic and allergenic substances that can produce many types of both local and systemic reactions. Of these, anaphylaxis is the most feared and the most common cause of sting-related deaths. Oropharyngeal stings, although rare, have the added potential to produce life-threatening airway obstruction via localized swelling. This threat is of particular concern to military personnel who operate in environments where stings are more likely to occur and where emergency medical resources are limited or lacking. This risk can be minimized if such victims are treated early and aggressively, even though they may initially present with minimal symptoms.

Entities:  

Mesh:

Year:  2002        PMID: 11873542

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  3 in total

Review 1.  Unusual reactions to hymenoptera stings: what should we keep in mind?

Authors:  Ervin Ç Mingomataj; Alketa H Bakiri; Alkerta Ibranji; Gunter J Sturm
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

Review 2.  Unusual Reactions to Hymenoptera Stings: Current Knowledge and Unmet Needs in the Pediatric Population.

Authors:  Riccardo Castagnoli; Mattia Giovannini; Francesca Mori; Simona Barni; Luca Pecoraro; Stefania Arasi; Francesca Saretta; Carla Mastrorilli; Lucia Liotti; Lucia Caminiti; Gunter Johannes Sturm; Gian Luigi Marseglia; Elio Novembre
Journal:  Front Med (Lausanne)       Date:  2021-11-26

Review 3.  Precision Medicine in Hymenoptera Venom Allergy: Diagnostics, Biomarkers, and Therapy of Different Endotypes and Phenotypes.

Authors:  Simon Blank; Johannes Grosch; Markus Ollert; Maria Beatrice Bilò
Journal:  Front Immunol       Date:  2020-10-22       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.